Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Compugen ( (CGEN) ) is now available.
On October 13, 2025, Compugen Ltd. announced the presentation of a pooled analysis of COM701 in three Phase 1 trials for patients with platinum-resistant ovarian cancer at the ESMO 2025 conference. The analysis, which included 60 evaluable patients, demonstrated that COM701 was well tolerated and showed durable responses, particularly in patients without liver metastases. This supports the rationale for its use as maintenance therapy in earlier treatment settings. Compugen is currently conducting the MAIA-ovarian trial to assess COM701 as a maintenance treatment in relapsed platinum-sensitive ovarian cancer, with interim analysis results expected by the end of 2026. The company is expanding trial sites to include locations in the U.S., Israel, and France, and anticipates its cash reserves will support operations into 2027.
The most recent analyst rating on (CGEN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Compugen stock, see the CGEN Stock Forecast page.
Spark’s Take on CGEN Stock
According to Spark, TipRanks’ AI Analyst, CGEN is a Neutral.
Compugen’s overall stock score reflects a balanced view of its financial challenges and strategic advancements. The company’s improved cash flow management and promising pipeline developments are offset by ongoing profitability issues and competitive pressures. The technical indicators suggest some positive momentum, but valuation concerns remain due to negative earnings.
To see Spark’s full report on CGEN stock, click here.
More about Compugen
Compugen Ltd. is a clinical-stage therapeutic discovery and development company that utilizes a predictive AI/ML powered computational discovery platform to identify new drug targets and biological pathways for cancer immunotherapies. The company has proprietary product candidates in Phase 1 development, including COM701 and COM902, and is involved in partnerships for further development of its technologies. Compugen is headquartered in Israel with offices in San Francisco, and its shares are listed on Nasdaq and the Tel Aviv Stock Exchange.
Average Trading Volume: 315,539
Technical Sentiment Signal: Buy
Current Market Cap: $173M
For an in-depth examination of CGEN stock, go to TipRanks’ Overview page.